Paul Tudor Jones’s Centessa Pharmaceuticals CNTA Stock Holding History

Paul Tudor Jones’s Portfolio CNTA Stock Details CNTA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-121,810	Closed	-$3.05M	–	3712
2025 Q4	$3.05M	Buy	121,810 +64,000	+111%	+$1.62M	0.01%	1498
2025 Q3	$1.4M	Buy	57,810 +6,959	+14%	+$124K	﹤0.01%	2037
2025 Q2	$668K	Sell	50,851 -55,074	-52%	-$698K	﹤0.01%	2398
2025 Q1	$1.52M	Buy	+105,925	New	+$1.73M	0.01%	1529
2021 Q3	–	Sell	-43,079	Closed	-$957K	–	2495
2021 Q2	$957K	Buy	+43,079	New	+$1.01M	0.02%	889

Other funds holding CNTA

MVM

Medicxi Ventures Management St. Helier, Jersey $177M AUM 212.06% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

IVLAV

Index Venture Life Associates VI St. Helier, Jersey $396M AUM 176.22% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

Paul Tudor Jones's CNTA Position: Q1 2026 in Review

Paul Tudor Jones sold out of Centessa Pharmaceuticals (CNTA) in Q1 2026, closing a stake of 121,810 shares — an estimated $3.05M sold.

Paul Tudor Jones first reported a position in CNTA in Q2 2021 and held it in 5 quarters. The position peaked at $3.05M in Q4 2025. 161 funds tracked by Wall St. Rank hold CNTA as of Q1 2026.

Paul Tudor Jones reported no remaining Centessa Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
Paul Tudor Jones sold 121,810 Centessa Pharmaceuticals shares in Q1 2026, an estimated $3.05M.
Paul Tudor Jones first reported a position in Centessa Pharmaceuticals in Q2 2021 and held it in 5 quarters.
Paul Tudor Jones's Centessa Pharmaceuticals position peaked at $3.05M in Q4 2025.
161 funds tracked by Wall St. Rank held Centessa Pharmaceuticals as of Q1 2026.

Based on Tudor Investment Corp's 13F filing for Q1 2026, filed 15 May 2026.